A Meta-analysis of the efficacy and safety of apatinib combined with SOX regime in patients with advanced gastric cancer
Objective:A Meta-analysis was conducted to systematically analyze the efficacy and safety of apatinib combined with SOX regime(oxaliplatin+tegafur)in patients with advanced gastric cancer.Methods:PubMed,Embase,Cochrane Library,ClinicalTrials.gov,WANFANG DATA and CNKI were searched for randomized controlled trials studying the efficacy and safety of apatinib combined with SOX in the treatment of advanced gastric cancer patients.Data were extracted from the included literature,and the main outcome indicators were as follows:objective response rate(ORR),disease control rate(DCR);secondary outcome indicators:partial response rate(PRR)and safety related indicators,including hypertension,proteinuria,hand-foot syndrome,diarrhea,oral mucositis,fatigue,leukopenia,thrombocytopenia.All statistical analyses were performed using meta package for R version 4.0.3.Results:1699 articles were retrieved and 28 articles with a total of 2110 subjects were ultimately included.Compared with SOX regimen,apatinib combined with SOX regimen improved DCR(OR=3.90,95%CI:3.15-4.83,P<0.001)and ORR(OR=2.73,95%CI:2.26-3.31,P<0.001),PRR(OR=2.33,95%CI:1.94-2.81,P<0.001),but increased hypertension(OR=2.47,95%CI:1.26-4.83,P=0.008),proteinuria(OR=2.16,95%CI:1.46-3.21,P<0.001),hand-foot syndrome(OR=2.19,95%CI:1.44-3.32,P<0.001).The difference was statistically significant.Conclusion:The results of this meta-analysis showed that apatinib combined with SOX regime was effective in the treatment of advanced gastric cancer with relatively mild adverse events,which is expected to be applied in clinical practice.
NETL
NSTL
万方数据
